Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
JERSEY CITY, N.J., Nov. 7, 2012
JERSEY CITY, N.J., Nov. 7, 2012 /PRNewswire/ --Optimer Pharmaceuticals, Inc.
(NASDAQ: OPTR) today announced that the Company will present at the below
listed investor conferences in November. The presentations will include an
overview of the company and an update on recent business activities.
o2012 Credit Suisse Healthcare Conference on Wednesday, November 14 at 1:00
PM Eastern time at The Arizona Biltmore in Phoenix.
oJefferies 2012 Global Healthcare Conference in London on Thursday,
November 15 at 6:20 AM Eastern time at the Waldorf Hilton in London, UK.
Live audio webcasts of the presentations will be accessible on the Investors
page of the Company's website at www.optimerpharma.com. Replays of the
presentations will be available at the same location for 30 days following the
Optimer Pharmaceuticals, Inc.is a global biopharmaceutical company focused on
developing and commercializing innovative hospital specialty products that
have a positive impact on society. Optimer developed DIFICID® (fidaxomicin)
tablets, anFDA-approved macrolide antibacterial drug for the treatment
ofClostridium difficile-associated diarrhea (CDAD) in adults 18 years of age
and older and is commercializing DIFICID in the US and Canada. Optimer also
received marketing authorization for fidaxomicin tablets in theEuropean
Unionwhere its partner,Astellas Pharma Europe, is commercializing
fidaxomicin under the trade name DIFICLIR™. The Company is exploring
marketing authorization in other parts of the world whereC. difficilehas
emerged as a serious health problem, includingAsia. Additional information
can be found at http://www.optimerpharma.com.
Optimer Pharmaceuticals, Inc.
David Walsey, Vice President, Investor Relations and Corporate Communications
Canale Communications, Inc.
Jason I. Spark, Senior Vice President
SOURCE Optimer Pharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.